clinical trial · NCT00829998
Zaleplon 10mg Capsules Under Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 40
HealthyZaleplon 10 mg CapsulesSonata® 10 mg Capsules
brief summary
The objective of this study was to compare the relative bioavailability of Zaleplon 10 mg Capsules manufactured by TEVA Pharmaceuticals USA and Sonata® 10 mg Capsules manufactured by Wyeth Laboratories in healthy, non-smoking adults under fasting conditions.
started
Feb 1, 2004
primary completion
Feb 1, 2004
completion
Feb 1, 2004
last updated
Aug 21, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative Bioavailability Study of Zaleplon 10mg Capsules Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol